Caris Life Sciences reports Q1 EPS 0c, consensus (2c)

Reports Q1 revenue $216.2M, consensus $209.67M. “We delivered another strong quarter with record performance for February and March following our January sales re-alignment. This performance underscores the continued demand for our platform and the strength of our comprehensive, patient-first approach,” said CEO David Dean Halbert. “We are also encouraged by the Achieve 1 data, including the blinded readout, which demonstrates the superior performance of our whole genome technology over inferior techniques such as methylation. We remain focused on strengthening Caris Detect through the incorporation of additional pillars in advance of our upcoming launch.”